Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02324582 · ClinicalTrials.gov registry record · Phase 1
MK-3475/BCG in High Risk Superficial Bladder Cancer
A Phase 1 study, sponsored by Southern Illinois University.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02324582 is a Phase 1 study that has completed, run by Southern Illinois University. The registered enrollment target is 18 participants.
The verdict
NCT02324582, a Phase 1 study, has completed, sponsored by Southern Illinois University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a single center Phase I safety and efficacy study of MK-3475 therapy used in combination with bladder infused BCG treatment for patients, 18 years or older, with high risk superficial bladder cancer (cancer not yet involving the muscle of the bladder wall) who have had removal of their bladder tumor. Patients will be enrolled to a single treatment group of a fixed dose of MK 3475 and BCG.
Interventions
- DRUG Intravenous MK-3475/ Intravesical BCG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2015-06 |
| Est. Completion | 2023-03-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02324582
The ClinicalTrials.gov registry entry for NCT02324582 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Southern Illinois University, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intravenous MK-3475/ Intravesical BCG is the first listed.
NCT02324582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02324582 about?
NCT02324582 is a clinical study titled "MK-3475/BCG in High Risk Superficial Bladder Cancer". This is a single center Phase I safety and efficacy study of MK-3475 therapy used in combination with bladder infused BCG treatment for patients, 18 years or older, with high risk superficial bladder cancer (cancer not yet involving the muscle of the bladder wall) who have had removal of their bladd...
What is the current status of trial NCT02324582?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2015-06. Estimated completion is 2023-03-27.
What interventions are being tested in trial NCT02324582?
The interventions under investigation include: Intravenous MK-3475/ Intravesical BCG (DRUG).
Who is sponsoring clinical trial NCT02324582?
This trial is sponsored by Southern Illinois University, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.